Business Context and Reporting Period
Company: DarioHealth Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: March 30, 2026
Event: Entry into a Material Definitive Agreement (Sales Agreement) for an "at-the-market" (ATM) equity offering program.
Key Financial Metrics and Transaction Details
- Offering Size: Up to $20,000,000 of common stock.
- Agent: A.G.P./Alliance Global Partners.
- Commission Rate: 3.00% of gross proceeds.
- Expense Reimbursement: Up to $35,000 initial out-of-pocket costs, plus up to $3,500 per calendar quarter, and up to $5,000 per program "refresh."
- Additional Fees: Up to $0.002 per share sold for FINRA filing fees and other costs.
- Use of Proceeds: Commercial/sales/marketing activities, R&D, M&A, corporate activities, repayment of indebtedness (specifically under the credit facility with Callodine Commercial Finance, LLC), and general working capital.
- Financial Performance: The filing text does not provide specific revenue, profit, cash flow, margin, or liquidity figures for the reporting period.
Material Changes and Agreements
The primary material change is the execution of the Sales Agreement on March 30, 2026, enabling the Company to sell shares via an ATM program. The agreement is governed by an effective shelf registration statement on Form S-3 (File No. 333-294454), declared effective on March 27, 2026. The Company retains the right to suspend or terminate the offering at any time and has no obligation to sell any shares.
Outlook, Risks, and Contingencies
- Termination Conditions: The offering terminates upon the sale of all shares, the expiration of the registration statement (third anniversary of the effective date), or termination by either party.
- Legal Opinion: An opinion regarding the legality of the shares was provided by Sullivan & Worcester LLP (Exhibit 5.1).
- Market Risk: Sales are subject to market conditions and the Company's discretion to suspend offers.
- Debt Repayment: Proceeds may be used to repay outstanding indebtedness, indicating potential liquidity management strategies.
Investor Verification Checklist
- Verify the current market price of DRIO common stock to assess potential dilution impact from the $20M offering.
- Review the Company's latest 10-K or 10-Q to confirm the outstanding balance of the credit facility with Callodine Commercial Finance, LLC.
- Monitor future filings for actual share sales volumes and proceeds generated under the ATM program.
- Check for any subsequent amendments to the Sales Agreement or the S-3 registration statement.